CLINICAL_TRIALS
ClinicalTrials.gov record update
Dual Anti-CD22/CD19 Chimeric Antigen Receptor-directed T Cells (CART2219.1) for Relapsed Refractory B-Lineage Leukaemia
This page presents selected fields from the linked source record. It does not add a medical interpretation.
Record identity and dates
- Source
- ClinicalTrials.gov
- Source record ID
- NCT05429905
- Title field or adapter rule
- protocolSection.identificationModule.officialTitle
- Ingested At
- 2026-04-28T10:39:17.256679+00:00
- Published At
- 2023-03-09T00:00:00+00:00
- Record Updated At
- 2023-03-09
- Timestamp Basis
- source retrieval time was not retained by the feed adapter
- Date limitation
- source retrieval time was not retained by the feed adapter
Fields recorded by this source
- protocolSection.conditionsModule.conditions
["Lymphoblastic Leukemia", "Lymphoblastic Leukemia, Acute, Childhood", "Lymphoblastic Leukemia in Children", "Lymphoblastic Leukemia, Acute Adult", "CAR"]- protocolSection.statusModule.lastUpdatePostDateStruct.date
"2023-03-09"- protocolSection.identificationModule.nctId
"NCT05429905"- protocolSection.identificationModule.officialTitle
"Dual Anti-CD22/CD19 Chimeric Antigen Receptor-directed T Cells (CART2219.1) for Relapsed Refractory B-Lineage Leukaemia"- protocolSection.statusModule.overallStatus
"UNKNOWN"- protocolSection.designModule.phases
["PHASE1", "PHASE2"]- protocolSection.statusModule.resultsFirstPostDateStruct.date
""
Study condition terms
Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.
This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.